Europe Hemoglobinopathies Market Report and Forecast 2024-2032

The global hemoglobinopathies market size was valued at USD 6.9 billion in 2023, with Europe holding a significant market share. It is driven by the rising prevalence of thalassemia and sickle cell anemia. The global market is expected to grow at a CAGR of 5.1% during the forecast period of 2024-2032, with the values likely to attain USD 15.9 billion by 2032.

Key Takeaways

• Recent data reports sickle cell disease as the leading rare disease in France with around 30,000 patients affected by the condition. The increasing prevalence of hemoglobinopathies in European countries is poised to directly impact the market demand for effective and affordable treatment solutions in coming years.
• One of the major Europe hemoglobinopathies market trends is the surge in drug approvals of innovative treatment therapies by the health regulatory bodies. In December 2023, the European Medicines Agency (EMA) approved the first gene therapy Casgevy (exagamglogene autotemcel) developed by Vertex Pharmaceuticals (Ireland) Limited to treat transfusion-dependent beta thalassemia and severe sickle cell disease.
• The market is witnessing a rise in strategic partnerships among the key market players to expand their presence in the European market. In March 2023, AddMedica and Abacus Medicine Pharma Services entered a partnership to commercialize their sickle cell disease therapy Siklos (hydroxyurea) in the Western Europe region.

Europe Hemoglobinopathies Market Analysis

Hemoglobinopathies are a group of inherited blood disorders that affect the structure, function, or production of the hemoglobin molecule. The condition is usually resulted due to genetic mutations that damage or deform the red blood cells. Sickle cell anemia and thalassemia are considered the most common types of hemoglobinopathies. The disorder presents a significant health challenge in Europe. Several factors such as technological advancements in screening and diagnostic tools, rigorous research, and development efforts, and rising regulatory support are expected to drive the Europe hemoglobinopathies market growth.

The increasing prevalence of hemoglobinopathies in Europe is poised to directly impact the market demand for effective and affordable treatment solutions. Recent data reports sickle cell disease as the leading rare disease in France with around 30,000 patients affected by the condition. The rising cases of the disease stimulate innovation in screening, diagnosis, and management strategies. Moreover, the heightened patient awareness coupled with the growing advocacy efforts for improved access to care and treatments for hemoglobinopathies is likely to bolster Europe hemoglobinopathies market demand in the forecast period.

The favorable regulatory environment in the region is expected to improve access to innovative therapies for the growing patient base as well as encourage investments from the key market players. In December 2023, the European Medicines Agency (EMA) granted approval to the first gene therapy Casgevy (exagamglogene autotemcel) developed by Ireland based Vertex Pharmaceuticals Limited to treat transfusion-dependent beta thalassemia and severe sickle cell disease in patients aged 12 or older. The medication employs CRISPR/Cas9 gene editing technology and has the potential to reduce the burden of frequent transfusions, thereby improving the patient’s quality of life and elevating Europe hemoglobinopathies market value.

A major market trend is the rise in strategic partnerships among the key market players to share expertise and resources and subsequently expand their presence in the European market. In March 2023, AddMedica (Specialty Pharma Company in France) and Abacus Medicine Pharma Services (a pharmaceutical company in England) entered a strategic partnership to commercialize their sickle cell disease therapy Siklos (hydroxyurea) for patients aged 2 years and above. It is to be applied in three countries of western Europe, including Belgium, the Netherlands, and Luxembourg. Siklos has the potential to prevent red blood cells from taking a sickle-celled shape and reduce the risk of vaso-occlusive crises (VOCs) in the affected people. The increased emphasis on marketing and distribution of sickle cell therapies to ensure the accessibility of treatment options in the region is anticipated to augment the market share in the forecast period.

Europe Hemoglobinopathies Market Segmentation

Market Breakup by Type

• Thalassemia
• Sickle Cell Disease
• Other Hb Variants Diseases

Market Breakup by Treatment

• Stem-Cell Transplantation
• Blood Transfusions
• Analgesics
• Antibiotics
• Ace Inhibitors
• Hydroxyurea
• Monoclonal Antibody Medication
• Others

Market Breakup by Test Type

• Routine Red Blood Cell (RBC) Count
• Genetic Testing
• Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC)
• Hemoglobin Isoelectric Focusing (Hb IEF)
• Hemoglobin electrophoresis (Hb ELP)
• Hemoglobin Solubility Test

Market Breakup by End User

• Hospitals and Clinics
• Diagnostics Laboratories
• Others

Market Breakup by Country

• United Kingdom
• Germany
• France
• Italy

Europe Hemoglobinopathies Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Bio-Rad Laboratories, Inc.
• Bristol-Myers Squibb Company
• Novartis AG
• Pfizer Limited
• Merck KGaA
• Alnylam Pharmaceuticals, Inc.
• Sanofi
• Neusoft Corporation
• Emmaus UK
• Biogen

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

FAQs

What is the Europe hemoglobinopathies market forecast outlook for 2024-2032?
The Europe hemoglobinopathies market is expected to be driven by the rising demand in the global market, which is anticipated to grow at a CAGR of 9.7% during the forecast period of 2024-2032 and is likely to reach a market value of USD 15.9 billion by 2032.

What are the major factors aiding the Europe hemoglobinopathies market demand?
The heightened patient awareness coupled with the growing advocacy efforts for improved access to care and treatments for hemoglobinopathies are fuelling the demand for the market.

What are the major Europe hemoglobinopathies market trends?
One of the significant trends in the market is the is the surge in drug approvals of innovative treatment therapies by the health regulatory bodies. In December 2023, the European Medicines Agency (EMA) approved the first gene therapy Casgevy (exagamglogene autotemcel) developed by Vertex Pharmaceuticals Limited to treat transfusion-dependent beta thalassemia and severe sickle cell disease.

What is the market segmentation based on the type?
Based on the type, the market is segmented into thalassemia, sickle cell disease, and other Hb variants diseases.

What are the various treatments available in the market?
Treatments available in the market include stem-cell transplantation, blood transfusions, analgesics, antibiotics, ace inhibitors, hydroxyurea, and monoclonal antibody medication, among others.

What is the market breakup by test type?
By test type, the market is divided into Routine Red Blood Cell (RBC) Count, Genetic Testing, Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC), Hemoglobin Isoelectric Focusing (Hb IEF), Hemoglobin electrophoresis (Hb ELP), and Hemoglobin Solubility Test.

What are the major end users of the market?
End users of the market are hospitals and clinics, diagnostics laboratories, among others.

What is the market segmentation by countries?
The market segmentation by countries includes the United Kingdom, Germany, France, and Italy.

Who are the key players involved in the Europe hemoglobinopathies market?
The key players in the market are Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Novartis AG, Pfizer Limited, Merck KGaA, Alnylam Pharmaceuticals, Inc., Sanofi, Neusoft Corporation, Emmaus UK, and Biogen.


This product will be delivered within 5-7 business days.